For the year ending 2025-12-31, FHTX made $30,909K in revenue. -$74,394K in net income. Net profit margin of -240.69%.
| Income Statement | 2025-12-31 | 2024-12-31 | ||
|---|---|---|---|---|
| Collaboration revenue | 30,909 | 22,602 | ||
| Research and development | 85,466 | 94,528 | ||
| General and administrative | 27,550 | 28,359 | ||
| Gain on lease modification | 1,632 | - | ||
| Impairment of long-lived assets | 5,914 | 2,398 | ||
| Total operating expenses | 117,298 | 125,285 | ||
| Loss from operations | -86,389 | -102,683 | ||
| Interest income | 8,745 | 11,900 | ||
| Other income, net | 3,361 | 4,163 | ||
| Total other income, net | 12,106 | 16,063 | ||
| Loss before income taxes | - | -86,620 | ||
| Net loss | -74,283 | -86,620 | ||
| Unrealized gains (losses) on marketable securities | -111 | 961 | ||
| Total other comprehensive gain (loss) | -111 | 961 | ||
| Total comprehensive loss | -74,394 | -85,659 | ||
| Basic EPS | -1.18 | -1.58 | ||
| Diluted EPS | -1.18 | -1.58 | ||
| Basic Average Shares | 62,980,959 | 54,899,432 | ||
| Diluted Average Shares | 62,980,959 | 54,899,432 | ||
Foghorn Therapeutics Inc. (FHTX)
Foghorn Therapeutics Inc. (FHTX)